Evaluation of Gum Bleeding in Patients Taking Oral Anticoagulants Therapy with Risks of Venous Thrombosis

Abstract

Introduction:

Anticoagulants play an important role in treatment to prevent the incidence of atherothrombotic events in patients on risks of cardiovascular, cerebrovascular and peripheral artery diseases. On the other hand, due to the use of these anticoagulants patients also present with some hemorrhagic conditions out of which epistaxis and bleeding gums are the most common.

Objectives: The purpose of this study was to identify the risk factors and side effects of anticoagulants in patients taking anticoagulant therapy.

Material and methods:

 This study was conducted in a tertiary care hospital during June 2021 to June 2022.

All the ethical measures were taken before research. Only the patients with risks of athero-thrombotic events were included. A total of 200 patients meeting the inclusion and exclusion criteria were enrolled in the study.

Detailed history and physical examination were done to meet the inclusion and exclusion criteria. Informed consent was obtained.

Results: The data was collected from 200 patients. The average age was 32.67±2.56 years. The mean bleeding time was 18.5 ± 6.2 min, varying from 5 min to 22 min. The bleeding incidence was 33%. Out of 200 patients, 17 patients had a bleeding time of more than 21.5 min but less than 25 min, 5 patients had minor bleeding and 1 patient had blood in urine due to internal bleeding which ceased after the termination of anti-platelet agents.

 Conclusion:

Safety measures should be considered with adjacent dose in patients taking anticoagulant therapy. Patients should be counselled about acute hemorrhagic events and initial procedures.